CY1113492T1 - MODIFIED PROTEIN FIELDS - Google Patents

MODIFIED PROTEIN FIELDS

Info

Publication number
CY1113492T1
CY1113492T1 CY20121101249T CY121101249T CY1113492T1 CY 1113492 T1 CY1113492 T1 CY 1113492T1 CY 20121101249 T CY20121101249 T CY 20121101249T CY 121101249 T CY121101249 T CY 121101249T CY 1113492 T1 CY1113492 T1 CY 1113492T1
Authority
CY
Cyprus
Prior art keywords
modified
domains
protein
modified protein
fields
Prior art date
Application number
CY20121101249T
Other languages
Greek (el)
Inventor
Jonathan H Davis
James Stafford Huston
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20070723539 external-priority patent/EP1999154B1/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1113492T1 publication Critical patent/CY1113492T1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια τροποποιημένη πρωτεΐνη πολλαπλών πεδίων που περιλαμβάνει τουλάχιστον δύο μη πανομοιότυπα τροποποιημένα πεδία, κάθε ένα από τα οποία περιέχει μια διεπιφάνεια αλληλεπίδρασης πρωτεΐνης-πρωτεΐνης που περιέχει τμήματα αλληλουχιών αμινοξέων που προέρχονται από δύο ή περισσότερα υπάρχοντα ομόλογα μητρικά πεδία, παρέχοντας επομένως στα τροποποιημένα πεδία ειδικότητες συγκρότησης διακριτές από τις ειδικότητες συγκρότησης των μητρικών πεδίων. Συγκεκριμένα, τα τροποποιημένα πεδία σχηματίζουν κατά προτίμηση ετεροδιμερή το ένα με το άλλο από το να σχηματίζουν ομοδιμερή. Επίσης περιλαμβάνονται μέθοδοι σχεδιασμού και χρήσης των τροποποιημένων πρωτεϊνών.The present invention provides a modified multi-domain protein comprising at least two non-identical modified domains, each of which contains a protein-protein interaction interface comprising fragments of amino acid sequences derived from two or more existing homologous parental domains, assembly field specialties distinct from the parent field assembly properties. In particular, the modified domains preferably form heterodimers with each other than form homodimers. Also included are methods for designing and using modified proteins.

CY20121101249T 2006-03-24 2012-12-21 MODIFIED PROTEIN FIELDS CY1113492T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78547406A 2006-03-24 2006-03-24
EP20070723539 EP1999154B1 (en) 2006-03-24 2007-03-23 Engineered heterodimeric protein domains

Publications (1)

Publication Number Publication Date
CY1113492T1 true CY1113492T1 (en) 2016-06-22

Family

ID=58448862

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101249T CY1113492T1 (en) 2006-03-24 2012-12-21 MODIFIED PROTEIN FIELDS

Country Status (1)

Country Link
CY (1) CY1113492T1 (en)

Similar Documents

Publication Publication Date Title
CY1122195T1 (en) SERPIN FUSION POLYPEPTIDES AND METHODS OF USING THEM
CY1120822T1 (en) SPECIAL SPECIFIC COMMITMENT TERRITORY
WO2007110205A3 (en) Engineered heterodimeric protein domains
CY1121632T1 (en) RV2386C TUBERCULOSIS PROTEIN, ITS COMPOSITIONS AND USES
BR112018012784A2 (en) nucleic acids encoding proline and alanine residue-rich repetitive amino acid sequences that have low repeat nucleotide sequences
CY1121962T1 (en) T CELL RECEPTORS
CY1117975T1 (en) STABILIZED FIELD COMPOSITIONS OF FIELDS, METHODS AND USES
CY1118008T1 (en) PARTICULAR BINDING PROTEINS AND THEIR USES
CY1119647T1 (en) ALUMINUM ACCESSORIES AND ACCESSORIES FOR ACCESSORIES
CY1114851T1 (en) IL-1BIT BINDING antibodies and their fragments
CY1118979T1 (en) ANTIBODIES DIRECTED AGAINST HER-3 AND USE OF THESE
CY1117351T1 (en) JNK-CELL SIGNIFICANT Peptide Suspensions - Signaling Pathway
CO7170123A2 (en) Complex of factor viii with xten and von willebrand factor protein and its uses
CY1121049T1 (en) INNOVATIVE SIGNAL SEQUENCES FOR IMPROVING PROTEIN EXPRESSIONS AND SECRETATION OF RECOVERY ENZYMES AND OTHER PROTEINS
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
CY1114584T1 (en) RECOVERABLE VACCINES AND USE OF THESE
BRPI0515649B8 (en) Process for preparing highly concentrated monoclonal antibody compositions
BR112014001573B8 (en) MULTIVALENT ANTIGEN FV MOLECULE
CO6280541A2 (en) MONOCLONAL ANTIBODIES OR FRAGMENTS OF THE SAME THAT JOIN THE HXAN RECEIVER OX40
WO2007133835A3 (en) Ras mutation and compositions and methods related thereto
BR112012004697B8 (en) method for purifying a polypeptide comprising a ch2/ch3 region
EA201100071A1 (en) NEW COMPOSITIONS AND METHODS
UY30925A1 (en) IMMUNOGLOBULIN FUSION PROTEINS AND ELABORATION METHODS
ATE447414T1 (en) USE OF ACTIVATED POLYMERS TO SEPARATE PROTEIN AND POLYPEPTIDE MULTIMERS
CY1123997T1 (en) NEW HUMAN SERUM ALBUMIN MUTATION